Table 2.
Completion of Therapy by Underlying Organism and Group Randomization in 88 Patients With Endemic Mycoses Enrolled in Study Comparing Conventional and Super-Bioavailability Itraconazole, 2018–2021
| Patients, No. | |||
|---|---|---|---|
| Treatment Group | Mycosis | Therapy Completed Through Day 180 | Withdrawal From Study |
| SUBA-itra | Blastomycosis | 8 | 1 |
| Coccidioidomycosis | 7 | 2 | |
| Histoplasmosis | 17 | 6 | |
| Sporotrichosis | 1 | 0 | |
| c-itra | Blastomycosis | 6 | 3 |
| Coccidioidomycosis | 3 | 1 | |
| Histoplasmosis | 23 | 5 | |
| Sporotrichosis | 3 | 2 | |
| Total | 68 | 20 | |
Abbreviations: c-itra, conventional itraconazole; SUBA-itra, super-bioavailability itraconazole.